Moxonidine in Patients Undergoing Vascular Surgery
Status:
Terminated
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
Investigating the perioperative effect of moxonidine. In a randomized double-blind fashion,
patients undergoing vascular surgery will receive moxonidine 0.2 mg or placebo from the day
before surgery until day 4 after surgery. Holter-EKG for 48 h, starting just before surgery.
Repeated 12-lead EKG, measurements of Troponin I and BNP, clinical visitations, follow-up
interviews at 6 and 12 months